Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | BLM | P54132 | 2/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | MPO | P05164 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL28059654 | 1.00 | KMT2A (0.74) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL78589 | 1.00 | KMT2A (0.74) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL7943446 | 1.00 | KMT2A (0.74) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL28149832 | 1.00 | KMT2A (0.74) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL11361648 | 0.99 | KMT2A (0.73) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL28496362 | 0.96 | KMT2A (0.68) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL8634348 | 0.96 | KMT2A (0.68) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL8634349 | 0.96 | KMT2A (0.68) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL4287653 | 0.95 | KMT2A (0.67) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL4551161 | 0.94 | KDM4E (0.65) | KMT2AKDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11260027-B2 | Donor organ pre-treatment formulation | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-03-01 | — | — | US | claimed |
| US-20200281190-A1 | ORGAN PRECONDITIONING FORMULATION WITH MITOCHONDRIAL ELONGATING AGENTS | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2020-09-10 | — | — | US | claimed |
| US-20180338963-A1 | DONOR ORGAN PRE-TREATMENT FORMULATION | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2018-11-29 | — | — | US | claimed |
| WO-2017019214-A1 | DONOR ORGAN PRE-TREATMENT FORMULATION | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-02-02 | — | — | WO | claimed |
| WO-2012146774-A1 | OLIGOSACCHARIDE CONJUGATES IN THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY | ENDOTIS PHARMA (FR) | 2012-11-01 | — | — | WO | claimed |
| US-6358501-B1 | USED AS INTERFACE-ACTIVE SUBSTANCES | GOLDSCHMIDT GMBH (DE) | 2002-03-19 | — | — | US | claimed |
| US-12023410-B2 | Micro/nanobubble solutions for tissue preservation and generation thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-02 | — | — | US | disclosed |
| CN-118217402-A | Combination therapy for C3 inhibition | 阿佩利斯制药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4380591-A1 | PEPTIDE LIQUID DROPLETS AND METHODS OF USING THE SAME | Ramot at Tel-Aviv University Ltd. (IL) | 2024-06-12 | — | — | EP | disclosed |
| CN-114395608-B | Cardiac single cell metabolism detection and analysis method | 中国医学科学院阜外医院 | 2024-05-28 | — | — | CN | disclosed |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2024-04-11 | — | — | US | disclosed |
| EP-4349363-A2 | DOSING REGIMENS | Apellis Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | SIXTH STREET LENDING PARTNERS | 2024-03-07 | — | — | US | disclosed |
| CN-1293250-A | Epidermal growth factor like protein and polynucleotide sequence for coding it | SHENGYUAN GENE DEV CO LTD SHAN (CN) | 2001-05-02 | — | — | CN | disclosed |
| CN-1293251-A | Human ankyrin and polynucleotide sequence for coding it | SHENGYUAN GENE DEV CO LTD SHAN (CN) | 2001-05-02 | — | — | CN | disclosed |
| CN-1292030-A | Modified forms of pullulanase | GENENCOR INT (US) | 2001-04-18 | — | — | CN | disclosed |
| CN-1291231-A | Human telomerase catalytic subunit | GERON CORP (US) | 2001-04-11 | — | — | CN | disclosed |
| CN-1279722-A | Gram-positive microorganisms formate pathway | GENENCOR INT (US) | 2001-01-10 | — | — | CN | disclosed |
| EP-0873304-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997019053-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | C3AR1, C5AR1, SERPINC1 | KMT2A 4132/4885KDM4E 4373/4885MAPT 4182/4885 |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | KMT2A 4187/4885KDM4E 4410/4885MAPT 2753/4885 |
| US-20200281190-A1 | ORGAN PRECONDITIONING FORMULATION WITH MITOCHONDRIAL ELONGATING AGENTS | TUFM, TFAM, PDF | KMT2A 3387/4885KDM4E 1981/4885MAPT 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.